🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,413 results for “Chinese” Clear

  1. JS004

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Limited Stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. JY231 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule active

    1 trial

  3. Jiangtang Tiaozhi recipe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type2 Diabetes

    phase 2 small molecule active

    1 trial

  4. LB1410

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  5. LEN+SIN+DEB-TACE+HAIC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma Non-resectable

    phase 2 other active

    1 trial

  6. LICSBR

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. LM-108 antibody and sintilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 2 small molecule active

    1 trial

  8. LP-98 20 mg

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV

    phase 2 small molecule active

    1 trial

  9. Lactulose

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Constipation

    phase 2 small molecule completed

    1 trial

  10. Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  11. Lenalidomide and Gemcitabine (Dose level 11)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T-cell Lymphomas (PTCL)

    phase 2 small molecule terminated

    1 trial

  12. Lenvima 4 mg Oral Capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  13. Letrozole

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Uterine Cervical Neoplasms

    phase 2 small molecule active

    1 trial

  14. Lidocaine Hydrochloride, Injectable

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Postoperative Chronic Pain

    phase 2 small molecule active

    1 trial

  15. Lithium Carbonate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  16. Loratadine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rhinitis, Allergic, Perennial

    phase 2 small molecule completed

    1 trial

  17. Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial

  18. Luspatercept

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HSCT

    phase 2 small molecule active

    1 trial

  19. Lusutrombopag Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Idiopathic Thrombocytopenic Purpura

    phase 2 small molecule completed

    1 trial

  20. MK-1045

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  21. MRG003

    Shanghai University of Traditional Chinese Medicine

    Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

    phase 2 small molecule active

    1 trial

  22. MRG003 combined with Dalpicicilip

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  23. MRG003 combined with Pucotenlimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  24. Marine active

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    "Hyperuricemia,Anserine"

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources